StockData
Viridian Therapeutics, Inc.DE logo

Viridian Therapeutics, Inc.DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30257% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.DE gross margin

Gross margin is gross profit as a percentage of revenue.

Viridian Therapeutics, Inc.DE's gross margin for the twelve months ending Dec 31, 2016 was 26.7%. For fiscal 2016 it was 26.7%, against 2.6% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2016Dec 31, 201626.7%+24.1
FY2015Dec 31, 20152.6%−45.5
FY2014Dec 31, 201448.1%−1.3
FY2013Dec 31, 201349.4%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2016Dec 31, 2016-36.0%–
Q3 FY2016Sep 30, 201636.0%–

More Viridian Therapeutics, Inc.DE figures

See a number that looks wrong?